Evidence map›Paper›PMID 34301262›Full record

ArticleJournal of biomedical science2021

AUY922 induces retinal toxicity through attenuating TRPM1.

Che-Hung Shen, Chi-Che Hsieh, Kuan-Ying Jiang, Chih-Yu Lin, Nai-Jung Chiang, Ting-Wei Li, Chun-Ting Yen, Wan-Ju Chen, Daw-Yang Hwang, Li-Tzong Chen

Open access · diamondAbstract read
In one paragraph

Article in Journal of biomedical science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Hsp90Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  3. Article
  4. American journal of ophthalmology case reports · 2024
    Article
  5. Review
  6. Is theMicroorganisms · 2023
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Che-Hung Shen *National Institute of Cancer Research, National Health Research Institutes, No. 367, Sheng-Li Rd., North District, Tainan, 70456, Taiwan. chshen@nhri.edu.tw.ORCID http://orcid.org/0000-0002-1309-6190
Chi-Che Hsieh *National Institute of Cancer Research, National Health Research Institutes, No. 367, Sheng-Li Rd., North District, Tainan, 70456, Taiwan.
Kuan-Ying JiangNational Institute of Cancer Research, National Health Research Institutes, No. 367, Sheng-Li Rd., North District, Tainan, 70456, Taiwan.
Chih-Yu LinNational Institute of Cancer Research, National Health Research Institutes, No. 367, Sheng-Li Rd., North District, Tainan, 70456, Taiwan.
Nai-Jung ChiangNational Institute of Cancer Research, National Health Research Institutes, No. 367, Sheng-Li Rd., North District, Tainan, 70456, Taiwan.
Ting-Wei LiDepartment of Life Sciences, National Cheng Kung University, Tainan, 704, Taiwan.
Chun-Ting YenInstitute of Molecular Medicine, National Cheng Kung University, Tainan, 704, Taiwan.
Wan-Ju ChenDepartment of Ophthalmology, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, 704, Taiwan.
Daw-Yang HwangNational Institute of Cancer Research, National Health Research Institutes, No. 367, Sheng-Li Rd., North District, Tainan, 70456, Taiwan.
Li-Tzong ChenNational Institute of Cancer Research, National Health Research Institutes, No. 367, Sheng-Li Rd., North District, Tainan, 70456, Taiwan. leochen@nhri.org.tw.
National Health Research Institutes · TWNational Cheng Kung University · TWKaohsiung Medical University · TWNational Cheng Kung University Hospital · TWNational Chung Hsing University · TW

Funding

Kaohsiung Medical University KMU-TC109A04-0Ministry of Science and Technology, Taiwan 107-2314-B-400-036-MY3
6 · The paper itself

Abstract

backgroundOcular adverse events are common dose-limiting toxicities in cancer patients treated with HSP90 inhibitors, such as AUY922; however, the pathology and molecular mechanisms that mediate AUY922-induced retinal toxicity remain undescribed.

methodsThe impact of AUY922 on mouse retinas and cell lines was comprehensively investigated using isobaric tags for relative and absolute quantitation (iTRAQ)‑based proteomic profiling and pathway enrichment analysis, immunohistochemistry and immunofluorescence staining, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, MTT assay, colony formation assay, and western blot analysis. The effect of AUY922 on the Transient Receptor Potential cation channel subfamily M member 1 (TRPM1)-HSP90 chaperone complex was characterized by coimmunoprecipitation. TRPM1-regulated gene expression was analyzed by RNAseq analysis and gene set enrichment analysis (GSEA). The role of TRPM1 was assessed using both loss-of-function and gain-of-function approaches.

resultsHere, we show that the treatment with AUY922 induced retinal damage and cell apoptosis, dysregulated the photoreceptor and retinal pigment epithelium (RPE) layers, and reduced TRPM1 expression. Proteomic profiling and functional annotation of differentially expressed proteins reveals that those related to stress responses, protein folding processes, regulation of apoptosis, cell cycle and growth, reactive oxygen species (ROS) response, cell junction assembly and adhesion regulation, and proton transmembrane transport were significantly enriched in AUY922-treated cells. We found that AUY922 triggered caspase-3-dependent cell apoptosis, increased ROS production and inhibited cell growth. We determined that TRPM1 is a bona fide HSP90 client and characterized that AUY922 may reduce TRPM1 expression by disrupting the CDC37-HSP90 chaperone complex. Additionally, GSEA revealed that TRPM1-regulated genes were associated with retinal morphogenesis in camera-type eyes and the JAK-STAT cascade. Finally, gain-of-function and loss-of-function analyses validated the finding that TRPM1 mediated the cell apoptosis, ROS production and growth inhibition induced by AUY922.

conclusionsOur study demonstrates the pathology of AUY922-induced retinal toxicity in vivo. TRPM1 is an HSP90 client, regulates photoreceptor morphology and function, and mediates AUY922-induced cytotoxicity.

Indexed as

Down-RegulationAnimalsAntineoplastic AgentsFemaleIsoxazolesMiceMice, NudeResorcinolsRetinaTRPM Cation Channels5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamideAntineoplastic AgentsIsoxazolesResorcinolsTrpm1 protein, mouseTRPM Cation ChannelsAUY922CDC37HSP90PhotoreceptorRetinal toxicityTRPM1

Identifiers

PMID34301262
PMCPMC8306347
OpenAlexW3185442213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.